First Japanese filing for antiplatelet contender prasugrel
This article was originally published in Scrip
Daiichi Sankyo has made the first approval filing in Japan for prasugrel, well over four years after the oral antiplatelet agent received its initial global approval in the EU.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.